A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01702181
Recruitment Status : Completed
First Posted : October 5, 2012
Last Update Posted : January 17, 2014
Information provided by (Responsible Party):
Otsuka Pharmaceutical Development & Commercialization, Inc.

Brief Summary:
The purpose of this study is to investigate the pharmacokinetics and safety of OPA-15406 in adult subjects with atopic dermatitis

Condition or disease Intervention/treatment Phase
Atopic Dermatitis Drug: OPA-15406 Drug: Tacrolimus Drug: Placebo Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 92 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multiple-Dose (0.3%, 1%, and 3% [w/w]), Randomized, Blinded, Vehicle- and Active Comparator-Controlled, Sequential Dose Cohorts, Multi-Center Trial to Assess the Safety, Pharmacokinetics, and Proof-of-Concept Efficacy of Topical OPA 15406 Ointment, Applied Twice Daily for 28 Days, in Adult Subjects With Atopic Dermatitis
Study Start Date : August 2012
Actual Primary Completion Date : December 2013
Actual Study Completion Date : December 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eczema
Drug Information available for: Tacrolimus

Arm Intervention/treatment
Placebo Comparator: Placebo
Matching placebo.
Drug: Placebo
Active Comparator: Tacrolimus
Tacrolimus 0.1% ointment twice daily for 28 days.
Drug: Tacrolimus
0.1% concentration of tacrolimus.
Other Name: Protopic

Experimental: OPA-15406 Drug: OPA-15406
0.3%, 1%, or 3% OPA-15406 topical ointment, applied twice daily for 28 days

Primary Outcome Measures :
  1. Number of subjects with AEs, SAEs, and % of clinically relevant changes from baseline in Draize Scale, physical examinations, vital signs, laboratory assessments, and electrocardiograms. [ Time Frame: 28 days ]
  2. Measurement of drug levels in the blood of treated patients [ Time Frame: 28 days ]

Secondary Outcome Measures :
  1. Investigator's Global Assessment (IGA) of Disease Severity at Week 4 [ Time Frame: 28 Days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult subjects 18-65 years of age
  • Diagnosis of atopic dermatitis (AD)
  • AD affecting at least 5% of total Body Surface Area (BSA) for Part 1 and at least 10% BSA for Part 2, not including face, neck, and head
  • Have had a positive but inadequate response to one or more treatment course of standard AD therapy including topical steroids, UV light A, narrowband UV B, and UV light B.

Exclusion Criteria:

-Use of systemic or topical therapy for contact or atopic dermatitis within 30 days of screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01702181

United States, Alabama
Mobile, Alabama, United States, 36608
United States, Arizona
Hot Springs, Arizona, United States, 71913
United States, California
Irvine, California, United States, 92697
United States, Florida
Orange Park, Florida, United States, 32073
Tampa, Florida, United States, 33609
United States, Indiana
Carmel, Indiana, United States, 46032
United States, New Jersey
Berlin, New Jersey, United States, 08009
United States, North Carolina
High Point, North Carolina, United States, 27262
United States, Oregon
Portland, Oregon, United States, 97210
United States, Texas
College Station, Texas, United States, 77845
Dallas, Texas, United States, 75230
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Otsuka Pharmaceutical Development & Commercialization, Inc.

Responsible Party: Otsuka Pharmaceutical Development & Commercialization, Inc. Identifier: NCT01702181     History of Changes
Other Study ID Numbers: 271-12-204
First Posted: October 5, 2012    Key Record Dates
Last Update Posted: January 17, 2014
Last Verified: January 2014

Keywords provided by Otsuka Pharmaceutical Development & Commercialization, Inc.:
Atopic Dermatitis, Eczema

Additional relevant MeSH terms:
Dermatitis, Atopic
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Immune System Diseases
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action